These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 4382323)
1. A GABA-related hypothesis on the mechanism of action of the antimotion sickness drugs. Giurgea CE; Moeyersoons FE; Evraerd AC Arch Int Pharmacodyn Ther; 1967 Mar; 166(1):238-51. PubMed ID: 4382323 [No Abstract] [Full Text] [Related]
3. The effect of the antihistaminic drugs on the central action of 5-hydroxytryptophan in mice. Rogóz Z; Skuza G; Sowińska H Pol J Pharmacol Pharm; 1981 Nov; 33(4):459-65. PubMed ID: 6120505 [TBL] [Abstract][Full Text] [Related]
4. 3-Indolylsuccinimides and 3-(3-pyrrolidinyl)indoles. Perron YG; Minor WF; Bierwagen ME; Ridlon SA; Pindell MH J Med Chem; 1966 Jan; 9(1):136-40. PubMed ID: 4381173 [No Abstract] [Full Text] [Related]
7. [Pharmacological characteristic of the product of condensation of phenamine with gamma-aminobutyric acid]. Aleksandrova AE; Smirnova SM Farmakol Toksikol; 1968; 31(5):525-6. PubMed ID: 5707719 [No Abstract] [Full Text] [Related]
8. Theory of antimotion sickness drug mechanisms. Wood CD; Graybiel A Aerosp Med; 1972 Mar; 43(3):249-52. PubMed ID: 4402925 [No Abstract] [Full Text] [Related]
9. [Effect of the antihistamine preparation, phencarol, on the central nervous system]. Kaminka ME; Roshchina LF; Mashkovskiĭ MD Farmakol Toksikol; 1980; 43(2):148-53. PubMed ID: 6108233 [TBL] [Abstract][Full Text] [Related]
10. ACTION OF SOME ANTI-MOTION SICKNESS DRUGS ON CENTRAL NYSTAGMUS. GIURGEA C; MOEYERSOONS F; VANDERAUWERA A Med Exp Int J Exp Med; 1963; 9():361-70. PubMed ID: 14084227 [No Abstract] [Full Text] [Related]
11. [Derivative of 4,9-dihydrothieno(2,3-b)benzo(e)thiepine--a new type of effective antihistaminic]. Metys J; Metysová J Acta Biol Med Ger; 1965; 15(6):871-3. PubMed ID: 4160911 [No Abstract] [Full Text] [Related]
12. Effects of azelastine hydrochloride, a novel anti-allergic drug, on the central nervous system. Kaneko T; Kitahara A; Ozaki S; Takizawa K; Yamatsu K Arzneimittelforschung; 1981; 31(8):1206-12. PubMed ID: 6117290 [TBL] [Abstract][Full Text] [Related]
13. [Model of motion sickness in dogs for assessing the effectiveness of pharmacological substances]. Radkevich LA Kosm Biol Aviakosm Med; 1977; 11(6):50-3. PubMed ID: 22775 [TBL] [Abstract][Full Text] [Related]
14. Antimotion sickness drug efficacy. Wood CD; Cramer DB; Graybiel A Otolaryngol Head Neck Surg; 1981; 89(6):1041-4. PubMed ID: 6121316 [No Abstract] [Full Text] [Related]
15. [The effect of the new Soviet antihistamine and antiserotonin preparation bikarfen on the central nervous system]. Kaminka ME; Kuksgauz NE; Andreeva NI Farmakol Toksikol; 1990; 53(4):21-3. PubMed ID: 1977614 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of histaminergic drugs in experimental motion sickness. Matsnev EI; Sigaleva EE J Vestib Res; 2007; 17(5-6):313-21. PubMed ID: 18626141 [TBL] [Abstract][Full Text] [Related]
17. [Some pharmacodynamical properties of niaprazine, a new antihistaminic agent]. Duchene-Marullaz P; Rispat G; Perriere JP; Hache J; Labrid C Therapie; 1971; 26(6):1203-9. PubMed ID: 4401719 [No Abstract] [Full Text] [Related]
18. Motion sickness is linked to nystagmus-related trigeminal brain stem input: a new hypothesis. Gupta VK Med Hypotheses; 2005; 64(6):1177-81. PubMed ID: 15823712 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacologic study of an antihistaminic derived from dibenzothiazepine]. Allain P; Frossard J; Weber A; Chareton JY Therapie; 1969; 24(6):1011-26. PubMed ID: 4391606 [No Abstract] [Full Text] [Related]
20. Pharmacologic properties of N-oxides of certain antihistaminic drugs. Gieldanowski J; Prastowski W Arch Immunol Ther Exp (Warsz); 1965; 13(6):657-65. PubMed ID: 4379532 [No Abstract] [Full Text] [Related] [Next] [New Search]